Yuqing Xiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuqing Xiang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dong Liu
School of Life Sciences, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong 226019, China
2 shared publications - Guoqiang Wan
Ministry of Education Key Laboratory of Model Animal for Disease Study, Department of Otolaryngology Head and Neck Surgery, Jiangsu Provincial Key Medical Discipline (Laboratory), the Affiliated Drum Tower Hospital of Medical School and the Model Animal Research Center of Medical School, Nanjing University, Nanjing 210008, China
1 shared publication - Qiuxiang Gu
Nantong Laboratory of Development and Diseases, School of Life Sciences, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong 226019, China
1 shared publication - Ruijun Shi
Institute of Special Environmental Medicine, Affiliated Hospital 2, Nantong University 1 , Nantong
1 shared publication - Shan Sun
ENT institute and Otorhinolaryngology Department of Eye & ENT Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200031, China
1 shared publication - Xin Wang
Institute of Special Environmental Medicine, Nantong University
1 shared publication
Latest Publications
- 28 October 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (12)
Irg1l regulates neuromast size via metabolic reprogramming to promote supporting cell proliferation
One of the most basic principles in embryonic development is ensuring the proper size of tissues and organs to meet functional needs. So far, an endogenous metabolite regulating organ size has not been described. The current study highlights itaconate, the product of Irg1, in regulating zebrafish neuromast size. Single-cell transcriptomic sequencing analysis of enzymes catalyzing metabolic processes revealed that irg1l, a homolog of Irg1, is highly expressed in supporting cells of developing neuromast in zebrafish. Deficiency of irg1l reduced the size of the neuromast and caused auditory dysfunction. Conversely, overexpression of irg1l resulted in increased size due to excessive proliferation of supporting cells. Notably, 4-octyl itaconate (4-OI), an itaconate derivative, treatment recapitulates the phenotype of irg1l overexpression and increases the neuromast size. Finally, we revealed that the Irg1l/itaconate axis induces metabolic reprogramming to promote activation of the Yap, drive supporting cell proliferation, and enlarge neuromast size. These findings provide a novel insight into the role of metabolites in organ development.
- 28 October 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (12)
Irg1l regulates neuromast size via metabolic reprogramming to promote supporting cell proliferation
One of the most basic principles in embryonic development is ensuring the proper size of tissues and organs to meet functional needs. So far, an endogenous metabolite regulating organ size has not been described. The current study highlights itaconate, the product of Irg1, in regulating zebrafish neuromast size. Single-cell transcriptomic sequencing analysis of enzymes catalyzing metabolic processes revealed that irg1l, a homolog of Irg1, is highly expressed in supporting cells of developing neuromast in zebrafish. Deficiency of irg1l reduced the size of the neuromast and caused auditory dysfunction. Conversely, overexpression of irg1l resulted in increased size due to excessive proliferation of supporting cells. Notably, 4-octyl itaconate (4-OI), an itaconate derivative, treatment recapitulates the phenotype of irg1l overexpression and increases the neuromast size. Finally, we revealed that the Irg1l/itaconate axis induces metabolic reprogramming to promote activation of the Yap, drive supporting cell proliferation, and enlarge neuromast size. These findings provide a novel insight into the role of metabolites in organ development.
- Top Cited PapersOpen Access
- 18 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5843
Brain Endothelial Cells in Blood–Brain Barrier Regulation and Neurological Therapy
Brain endothelial cells (BECs) constitute the core component of the blood–brain barrier (BBB), regulating substance exchange between blood and the brain parenchyma to maintain central nervous system homeostasis. In pathological states, the BBB exhibits the disruption of tight junctions, endothelial cell (EC) damage, and increased permeability, accompanied by neuroinflammation, oxidative stress, and abnormal molecular signaling pathways, leading to neurotoxic effects in the brain parenchyma and exacerbating neurodegeneration and disease progression. This review systematically summarizes the developmental origin, structural characteristics, and pathological mechanisms of BECs in diseases such as Alzheimer’s disease, multiple sclerosis, stroke, and glioblastoma with a particular focus on the regulatory mechanisms of the Wnt/β-catenin and VEGF signaling pathways. By integrating the latest research advances, this review aims to provide a comprehensive perspective for understanding the role of BECs in physiological and pathological states and to provide a theoretical basis for the development of BBB-based therapeutic approaches for neurological diseases.
- 18 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5843
Top Cited PapersOpen AccessBrain Endothelial Cells in Blood–Brain Barrier Regulation and Neurological Therapy
Brain endothelial cells (BECs) constitute the core component of the blood–brain barrier (BBB), regulating substance exchange between blood and the brain parenchyma to maintain central nervous system homeostasis. In pathological states, the BBB exhibits the disruption of tight junctions, endothelial cell (EC) damage, and increased permeability, accompanied by neuroinflammation, oxidative stress, and abnormal molecular signaling pathways, leading to neurotoxic effects in the brain parenchyma and exacerbating neurodegeneration and disease progression. This review systematically summarizes the developmental origin, structural characteristics, and pathological mechanisms of BECs in diseases such as Alzheimer’s disease, multiple sclerosis, stroke, and glioblastoma with a particular focus on the regulatory mechanisms of the Wnt/β-catenin and VEGF signaling pathways. By integrating the latest research advances, this review aims to provide a comprehensive perspective for understanding the role of BECs in physiological and pathological states and to provide a theoretical basis for the development of BBB-based therapeutic approaches for neurological diseases.